Published in J Med Chem on August 11, 2005
Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging (2007) 1.23
Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des (2008) 1.00
Synthesis of New 6-{[ω-(Dialkylamino(heterocyclyl)alkyl]thio}-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline-2-ones and Evaluation of their Anticancer and Antimicrobial Activities. Sci Pharm (2011) 0.89
Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain. Neoplasia (2013) 0.85
A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline. Ann Nucl Med (2013) 0.80
Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. Mol Imaging Biol (2010) 0.77
What oncologists need and require from nuclear medicine. Eur J Nucl Med Mol Imaging (2008) 0.77
Stroma targeting nuclear imaging and radiopharmaceuticals. Int J Mol Imaging (2012) 0.75
PET detection of epidermal growth factor receptor in colorectal cancer: a real predictor of response to cetuximab treatment? Eur J Nucl Med Mol Imaging (2007) 0.75
Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging. Front Pharmacol (2014) 0.75
A quinazoline-derivative DOTA-type gallium(III) complex for targeting epidermal growth factor receptors: synthesis, characterisation and biological studies. J Biol Inorg Chem (2008) 0.75
ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep (2002) 2.61
Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine. J Am Coll Cardiol (2009) 1.54
The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Cancer Biol Ther (2004) 1.50
Cisplatin-induced activation of the EGF receptor. Oncogene (2002) 1.48
Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia. J Biol Chem (2002) 1.42
Information-theoretic analysis of phenotype changes in early stages of carcinogenesis. Proc Natl Acad Sci U S A (2010) 1.24
On a fundamental structure of gene networks in living cells. Proc Natl Acad Sci U S A (2012) 1.21
EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med (2005) 1.15
Convergence of logic of cellular regulation in different premalignant cells by an information theoretic approach. BMC Syst Biol (2011) 1.13
Active Src elevates the expression of beta-catenin by enhancement of cap-dependent translation. Mol Cell Biol (2005) 1.12
Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res (2013) 1.12
The pp60c-Src inhibitor PP1 is non-competitive against ATP. FEBS Lett (2003) 1.11
Shift from apoptotic to necrotic cell death during human papillomavirus-induced transformation of keratinocytes. J Biol Chem (2009) 1.11
Automated radiochemical synthesis of [18F]FBEM: a thiol reactive synthon for radiofluorination of peptides and proteins. Appl Radiat Isot (2010) 1.09
Localization of parathyroid adenoma by ¹¹C-choline PET/CT: preliminary results. Clin Nucl Med (2014) 1.08
Killing time for cancer cells. Nat Rev Cancer (2005) 1.08
Molecular imaging of chemokine receptor CXCR4. Theranostics (2013) 1.04
Anomalous features of EMT during keratinocyte transformation. PLoS One (2008) 1.03
Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry (2002) 1.03
Optimization of energy-consuming pathways towards rapid growth in HPV-transformed cells. PLoS One (2007) 1.02
Targeting the EGFR and the PKB pathway in cancer. Curr Opin Cell Biol (2009) 1.02
Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR. Nat Biotechnol (2002) 1.01
Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des (2008) 1.00
Reducing health disparities: strategy planning and implementation in Israel's largest health care organization. Health Serv Res (2011) 0.99
Chelator-free (64)Cu-integrated gold nanomaterials for positron emission tomography imaging guided photothermal cancer therapy. ACS Nano (2014) 0.96
Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther (2002) 0.96
Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100. Mol Imaging Biol (2012) 0.96
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res (2002) 0.94
Cancer molecular imaging: radionuclide-based biomarkers of the epidermal growth factor receptor (EGFR). Curr Top Med Chem (2007) 0.93
Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors. Nucl Med Biol (2004) 0.92
Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol (2007) 0.92
A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. Cell Signal (2011) 0.92
EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice. Clin Cancer Res (2010) 0.92
Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J Biol Chem (2003) 0.92
Up-regulation of AMP-activated protein kinase in cancer cell lines is mediated through c-Src activation. J Biol Chem (2011) 0.92
PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors. IUBMB Life (2012) 0.90
Intrinsically radioactive [64Cu]CuInS/ZnS quantum dots for PET and optical imaging: improved radiochemical stability and controllable Cerenkov luminescence. ACS Nano (2015) 0.90
CXCR4 chemokine receptor overview: biology, pathology and applications in imaging and therapy. Theranostics (2013) 0.89
Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials (2005) 0.88
Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem (2003) 0.87
Targeted cancer therapy: promise and reality. Adv Cancer Res (2007) 0.87
Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem (2004) 0.86
Poly(I:C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier. Pharm Res (2010) 0.85
The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety--an EGFR putative irreversible inhibitor. Appl Radiat Isot (2007) 0.85
One-pot two-step radiosynthesis of a new (18)F-labeled thiol reactive prosthetic group and its conjugate for insulinoma imaging. Mol Pharm (2014) 0.85
A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway. Biochemistry (2007) 0.85
Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug. Int J Cancer (2002) 0.85
Imaging tumor-induced sentinel lymph node lymphangiogenesis with LyP-1 peptide. Amino Acids (2011) 0.84
A cellular screening assay to test the ability of PKR to induce cell death in mammalian cells. Mol Ther (2005) 0.84
Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovasc Res (2004) 0.83
Gating, enhanced gating, and beyond: information utilization strategies for motion management, applied to preclinical PET. EJNMMI Res (2013) 0.83
Loss of robustness and addiction to IGF1 during early keratinocyte transformation by human Papilloma virus 16. PLoS One (2007) 0.82
64Cu-labeled lissamine rhodamine B: a promising PET radiotracer targeting tumor mitochondria. Mol Pharm (2011) 0.82
RNA molecules as anti-cancer agents. Semin Cancer Biol (2004) 0.82
Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt). J Med Chem (2011) 0.82
Synthesis and structure-activity relationship studies of peptidomimetic PKB/Akt inhibitors: the significance of backbone interactions. Bioorg Med Chem (2010) 0.82
Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride. Appl Radiat Isot (2003) 0.81
Tumor specific activation of PKR as a non-toxic modality of cancer treatment. Semin Cancer Biol (2003) 0.81
Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors). Cancer Lett (2006) 0.81
Expression and purification of active PKB kinase from Escherichia coli. Protein Expr Purif (2005) 0.81
A color discriminating broad range cell staining technology for early detection of cell transformation. J Carcinog (2009) 0.81
Novel method for the synthesis of urea backbone cyclic peptides using new Alloc-protected glycine building units. J Pept Sci (2010) 0.81
Targeted cancer immunotherapy. Curr Opin Pharmacol (2013) 0.81
Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. Bioorg Med Chem (2011) 0.80
Contribution of gross chromosomal changes to HPV16-induced transformation. Mol Biosyst (2011) 0.80
Heterogeneity of gene expression in murine squamous cell carcinoma development-the same tumor by different means. PLoS One (2013) 0.80
ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur J Pharmacol (2007) 0.79
Evaluation of 64Cu-labeled acridinium cation: a PET radiotracer targeting tumor mitochondria. Bioconjug Chem (2011) 0.79
Molecular targeting of CEACAM6 using antibody probes of different sizes. J Control Release (2012) 0.79
Feeling vigorous and the risks of all-cause mortality, ischemic heart disease, and diabetes: a 20-year follow-up of healthy employees. Psychosom Med (2010) 0.79
Work-based predictors of mortality: a 20-year follow-up of healthy employees. Health Psychol (2011) 0.78
PET molecular imaging of angiogenesis with a multiple tyrosine kinase receptor-targeted agent in a rat model of myocardial infarction. Mol Imaging Biol (2015) 0.78
Microwave-assisted solid-phase aza-peptide synthesis: aza scan of a PKB/Akt inhibitor using aza-arginine and aza-proline precursors. J Org Chem (2011) 0.78
Structure--activity relationship and preclinical evaluation of carbon-11-labeled ammonium salts as PET--myocardial perfusion imaging agents. Mol Imaging Biol (2012) 0.78
Subunit S5a of the 26S proteasome is regulated by antiapoptotic signals. FEBS J (2007) 0.78
The effect of early and late treatment with the tyrphostin AG-556 on the progression of experimental autoimmune myocarditis. Exp Mol Pathol (2004) 0.77
EGF receptor family: twisting targets for improved cancer therapies. Growth Factors (2014) 0.77
Optimization of liganded polyethylenimine polyethylene glycol vector for nucleic acid delivery. Bioconjug Chem (2014) 0.77
Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. Mol Imaging Biol (2010) 0.77
The effect of tyrphostin AG-556 on intimal thickening in a mouse model of arterial injury. Exp Mol Pathol (2005) 0.77
Tyrphostin AG-556 reduces myocardial infarct size and improves cardiac performance in the rat. Exp Mol Pathol (2003) 0.76
The inhibition of Ras farnesylation leads to an increase in p27Kip1 and G1 cell cycle arrest. Eur J Biochem (2003) 0.76
Activation of dsRNA dependent protein kinase PKR in Karpas299 does not lead to cell death. Cancer Biol Ther (2005) 0.76
The complex regulation of HIC (Human I-mfa domain containing protein) expression. PLoS One (2009) 0.76
Studying protein-peptide interactions using benzophenone units: a case study of protein kinase B/Akt and its inhibitor PTR6154. Anal Biochem (2011) 0.76
Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-1295. Transplantation (2002) 0.75
The closure of Sugen. Nat Biotechnol (2003) 0.75